Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Drug Discovery Research Collaboration

By HospiMedica staff writers
Posted on 20 Jul 2006
The Translational Genomics Research Institute (TGen; Phoenix, AZ, USA) and GE Healthcare (Chalfont St. More...
Giles, UK) have announced a strategic alliance designed to employ sophisticated cellular genomics technologies and strategies to improve and accelerate the discovery and development of new drugs. This research collaboration will support the shared goals of translating basic genomic research into early health systems for some of the most pressing problems facing healthcare today.

TGen is focused on rapidly translating genomic developments into earlier diagnoses and more effective treatments that directly benefit patient care. "This collaboration could result in a better understanding of the biological mechanisms involved in oncology, many of which are not currently well understood by the medical community,” said Spyro Mousses Ph.D., director of Pharmaceutical Genomics and Cancer Drug Development at TGen. "The advanced imaging systems provided by GE allow us to observe cellular morphology more clearly and perform cytometry at an unprecedented rate. Most importantly, we can more accurately collect multi-parametric information about how cells are responding to specific genetic perturbations and to specific drug exposures.”

GE Healthcare's IN cell analyzer imaging systems are used by researchers in pharmaceutical and academic labs to assess a range of cellular processes in disease definition and drug development. TGen's high throughput cellular analysis research program will be equipped with both the IN cell analyzer 3000 and 1000. The new imaging systems will enable TGen investigators to functionally study the genome to identify and characterize cancer-associated genes that can be used to help develop more targeted medicines.

TGen is a non-profit organization focused on developing earlier diagnostics and better treatments. Translational genomics research is a somewhat new field employing innovative developments arising from the Human Genome Project and applying them to the development of diagnostics, prognostics, and therapies for cancer, neurological disorders, diabetes, and other complicated diseases.

GE Healthcare's expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians worldwide provide new ways to predict, diagnose, inform and treat disease.



Related Links:
Translational Genomics Research Institute
GE Healthcare

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.